HEALTHCARE INSIGHTS
HEALTHCARE INSIGHTS
  • Home
  • #Global Trends
  • #Vietnam
  • #M&A
  • #Regulations
  • #Knowledge
    • #Corporate Wellness
    • #Human Resources
    • #Capability Development
    HEALTHCARE INSIGHTS
    HEALTHCARE INSIGHTS

    Category: Uncategorized

    France recalls Novalac formula batch: Manufacturer isolates root cause of color and odor anomalies

    15/06/2026 Published by Pharma Biz

    The French government has officially confirmed the voluntary preventive recall of an infant formula batch executed by Novalac following a... Read more

    Category: Uncategorized
    Tags: #Global Trends

    Vietnam Ministry of Health orders urgent recall of French Novalac Allernova AR infant formula batch

    15/06/2026 Published by Pharma Biz

    The Vietnam Food Safety Administration, operating under the Ministry of Health, has officially dispatched an urgent directive to regional health... Read more

    Category: Uncategorized
    Tags: #Vietnam

    FDA clears expanded approval for Sanofi’s type 1 diabetes drug Tzield in Stage 3 pediatric cohorts

    13/06/2026 Published by Pharma Biz

    The U.S. Food and Drug Administration (FDA) has formally approved the expanded clinical utilization of Sanofi’s injectable metabolic therapy, Tzield.... Read more

    Category: Uncategorized
    Tags: #Global Trends
    13/06/2026 Published by Pharma Biz

    Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, has formally applauded the decision issued by... Read more

    Category: Uncategorized
    Tags: #Global Trends

    Gedeon Richter and Hetero Labs secure global alliance to develop and market generic Ozempic®

    12/06/2026 Published by Pharma Biz

    Gedeon Richter Plc. (Hungary) and Hetero Labs Ltd. (India) have officially announced the execution of a definitive global collaboration agreement... Read more

    Category: Uncategorized
    Tags: #M&A

    Chiesi Group finalizes $1.9 billion acquisition of KalVista Pharmaceuticals to expand rare disease footprint

    12/06/2026 Published by Pharma Biz

    Chiesi Group, an international research-focused biopharmaceutical corporation and certified B Corp, has officially finalized its corporate acquisition of KalVista Pharmaceuticals... Read more

    Category: Uncategorized
    Tags: #M&A

    Amgen taps Duke Clinical Research Institute to independently review Tavneos data amid FDA withdrawal proposal

    12/06/2026 Published by Pharma Biz

    U.S. biotechnology giant Amgen has officially retained an independent third-party research institution to conduct an un-biased evaluation of the clinical... Read more

    Category: Uncategorized
    Tags: #Global Trends

    Novartis’ $12 billion RNA asset del-brax logs clinical trial victory in rare muscle-wasting disease

    12/06/2026 Published by Pharma Biz

    Swiss pharmaceutical giant Novartis has officially announced that its investigational RNA therapeutic, delpacibart braxlosiran (del-brax), successfully satisfied its primary biomarker... Read more

    Category: Uncategorized

    Takeda’s $4 billion TYK2 inhibitor zasocitinib outperforms Bristol Myers’ Sotyktu in head-to-head psoriasis trial

    12/06/2026 Published by Pharma Biz

    Japanese drugmaker Takeda has officially announced positive top-line readouts from a head-to-head clinical trial, demonstrating that its investigational autoimmune candidate,... Read more

    Category: Uncategorized
    Tags: #Global Trends

    Posts pagination

    Previous page Page 1 … Page 8 Page 9 Page 10 … Page 156 Next page

    Facebook

    Map

    Workday: Monday to Friday
    Working hours: 8am to 5pm
    Address: 8th floor, Hyco 4 building, 205A Nguyen Xi Street, Binh Thanh Ward, HCMC

    Please enable JavaScript in your browser to complete this form.
    Get Your Weekly Market Insights Stay informed on Vietnam's market & Healthcare Alliance updates
    Loading

    Online Members

    Recent Comments

    • GauTruc on New Biotech Startup Secures $125 Million to Advance Pain Medication
    HEALTHCARE INSIGHTS
    All rights reserved